{"id":3170,"date":"2026-04-13T11:38:25","date_gmt":"2026-04-13T11:38:25","guid":{"rendered":"https:\/\/www.inbody.in\/blog\/?p=3170"},"modified":"2026-10-16T05:50:22","modified_gmt":"2026-10-16T05:50:22","slug":"semaglutide-muscle-loss-what-glp-1-drugs-do-to-your-body","status":"publish","type":"post","link":"https:\/\/www.inbody.in\/blog\/semaglutide-muscle-loss-what-glp-1-drugs-do-to-your-body","title":{"rendered":"GLP-1 in India: How to Lose Fat, Not Muscle (2026)"},"content":{"rendered":"

GLP-1 in India: How to Lose Fat, Not Muscle (2026)<\/h2>\n

The scale is dropping faster than it ever has. That is the appeal of GLP-1 medicines, and in India, since generic semaglutide arrived in March 2026, more people than ever are hearing about them from doctors, colleagues and WhatsApp groups. What gets talked about less is what exactly the scale is measuring. When someone loses 12 kg on one of these medicines, some of that is fat. Some is lean mass<\/strong>. And a fraction of the lean mass is muscle.<\/p>\n

This guide covers GLP-1 muscle loss<\/strong> in plain terms: what the large trials measured, why the numbers vary, what Indian readers should keep in mind, how to protect muscle, and how a body composition scan can help you and your doctor see what the weighing scale cannot. It is educational. These are prescription medicines, and every decision about starting, changing or stopping one belongs to you and your doctor.<\/p>\n

Lean Mass Is Not the Same as Muscle<\/h2>\n

Before any numbers, one definition matters. Lean mass<\/strong> (or fat-free mass) is everything in your body that is not fat: muscle, but also organs, bone, connective tissue and water. When a scan says “lean mass fell by 3 kg”, it does not follow that 3 kg of muscle disappeared. A review published in Obesity Reviews<\/em> in 2026 made the point directly: “lean”, “fat-free” and “skeletal muscle” mass are not synonyms, and the numbers depend on the measurement method.<\/p>\n

Keep that in mind as you read the trial figures below. They describe lean mass, which is an upper bound on muscle loss, not a direct count.<\/p>\n

What the Big Trials Measured<\/h2>\n

Two trials used DXA scans to split weight loss into fat and lean tissue:<\/p>\n\n\n\n\n\n\n
Trial (DXA substudy)<\/th>\nPeople scanned<\/th>\nWeight change<\/th>\nFat mass<\/th>\nLean mass<\/th>\n<\/tr>\n<\/thead>\n
STEP 1 (semaglutide, 68 weeks)<\/td>\n140<\/td>\n-15.0% (placebo -3.6%)<\/td>\n-19.3%<\/td>\n-9.7%<\/td>\n<\/tr>\n
SURMOUNT-1 (tirzepatide, 72 weeks)<\/td>\n160<\/td>\n-21.3% (placebo -5.3%)<\/td>\n-33.9%<\/td>\n-10.9%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Sources: the STEP 1 DXA abstract<\/a> and the SURMOUNT-1 DXA substudy<\/a>.<\/p>\n

Turning those percentages into “how much of the weight I lost was lean” gives different answers. A 2025 joint advisory on nutrition and exercise with these medicines, published in Obesity<\/a>, reports that in STEP 1, of an average 13.6 kg weight reduction, about 8.3 kg (62%) was fat and about 5.3 kg (38%) was lean mass. In the SURMOUNT-1 substudy, roughly 26% of the weight lost on tirzepatide was lean. A 2025 meta-analysis of nine placebo-controlled trials put it at about 30%.<\/p>\n

Do not average these. The trials used different drugs, populations and methods. The honest range from the research is somewhere around a quarter to well over a third of the weight lost being lean tissue, and the advisory notes that roughly half of lean tissue is skeletal muscle.<\/p>\n

Dieting Itself Costs Lean Mass<\/h2>\n

This is the part that gets lost in headlines. In the SURMOUNT-1 substudy, people on placebo, who were simply on a lifestyle programme, also lost lean mass: about a quarter of their weight loss. Losing weight by any route tends to cost some lean tissue unless you take deliberate steps to protect it. These medicines are not uniquely “muscle-wasting”. They make large weight loss possible, which makes the protection plan more important.<\/p>\n

The studies also have limits. Only a small subset of each trial had DXA scans. Most participants were women, many were White, and the DXA analyses were not the main trial question. We do not have large, Indian body composition datasets for these medicines yet.<\/p>\n

Why Indians Should Pay Particular Attention<\/h2>\n

South Asians tend to start with less muscle for the same BMI and more fat around the abdomen, the thin-fat pattern we cover in our post on thin-fat syndrome in India<\/a>. If your starting muscle reserve is already modest, losing a similar percentage leaves you with less to spare. Indian expert groups that have published guidance on GLP-1 therapy this year, as reported in the Indian press, have emphasised the same points: assess nutrition and muscle at baseline, prioritise good-quality protein, combine nutrition with resistance exercise, and use simple strength tests such as handgrip and chair-stand in people at higher risk. The reports we reviewed did not specify a protein number, so we have not quoted one as “the Indian guideline”.<\/p>\n

\n\"InBody
A scan separates fat, lean mass and body water, which the weighing scale cannot<\/figcaption><\/figure>\n

Protecting Muscle: What Guidelines Propose<\/h2>\n

The advisory above lays out the commonly proposed approach. These are what the document proposes for general adults, not a prescription for you, and your doctor or dietitian should personalise them, especially if you have kidney disease or other conditions.<\/p>\n